Marinomed’s first marketed product based on the Carragelose® platform is a cold virus-blocking nasal spray for the prevention and treatment of common cold. The product is a sterile nasal spray that is marketed in the EU and globally in a growing number of countries via renowned partners.
The product is registered as medical device class IIa in Europe since 2007 and is sold as an over-the-counter (OTC) product allowing direct to consumer marketing.
Key claims in EU:
- Can shorten the duration and severity of common cold symptoms
- Can reduce the resurgence of virus-related symptoms of common cold
Claims may vary in non-EU countries dependent on the regulatory status.
Clinical studies were conducted with the virus-blocking nasal spray against common cold, in adults and in small children.
Marinomed has received patents worldwide to protect the Carragelose® platform and its products. Patent protection lasts until end of 2027; the core patent was granted in the EU in 2010.